- FTC Sends Cease and Desist Demands to 10 Companies Suspected of Making Diabetes Treatment Claims without the Required Scientific Evidence ( )
- FTC, Georgia Attorney General Sue Stem Cell Institute of America Co-Founders for Deceptive Joint Pain Cure-All Marketing Scheme ( )
- Refunds Coming to Consumers Who Bought Deceptively Marketed Willow Curve Device ( )
- FTC Testifies Before House Energy and Commerce Subcommittee on Legislation to Modify the Commission’s Authority and Address Challenges Facing the Agency ( )
- FTC Sues PPE Marketer for Falsely Promising Quick Delivery of N95 Facemasks ( )
- Promoter of $23,000 COVID-19 “Treatment” Plan Barred from Making Bogus Health Claims ( )
- FTC Approves Final Administrative Consent Orders against Companies that Deceptively Marketed Fish Oil Supplements with False Claims They Were Clinically Proven to Treat Liver Disease ( )
- Federal Trade Commission, FDA Warn Five Companies That May Be Illegally Selling Dietary Supplements Claiming to Treat Infertility ( )
- FTC Announces Latest Enforcement Action Halting Deceptive CBD Product Marketing ( )
- The FTC Directed 30 More Marketers to Stop Making Unsupported Claims That Their Products and Therapies Can Effectively Prevent or Treat COVID-19 ( )
- FTC Testifies before Congress on its Work to Curb COVID-19 Scams and Warn Consumers about Pandemic-related Frauds, Cons, and Swindles ( )
- FTC Testifies Before Congress on its Work to Protect Consumers from COVID-19 Scams, and Threats to its Ability to Return Money to Victims of Illegal Conduct ( )
- One Year into COVID-19 Pandemic, New FTC Staff Report Highlights Agency’s Ongoing Efforts to Protect Consumers ( )
- In First Action Under COVID-19 Consumer Protection Act, FTC Seeks Monetary Penalties for Deceptive Marketing of Purported Coronavirus Treatments ( )
- Companies Settle FTC Charges that They Deceptively Marketed Fish Oil Supplements with False Claims They Were Clinically Proven to Treat Liver Disease ( )
- FTC Approves Final Administrative Consent Orders against Sellers of Deceptively Marketed CBD Products ( )
- Publisher Will Pay More Than $2 Million to Settle FTC Charges That It Targeted Seniors with Phony Diabetes Cure and Money Making Schemes ( )
- One of the Defendants Behind Alleged Sham Health Insurance Scheme Agrees to Settle FTC Charges ( )
- FTC Announces Crackdown on Deceptively Marketed CBD Products ( )
- FTC Issues Consumer Tips for Avoiding COVID-19 Vaccine Scams ( )
- FTC Returns Almost $775,000 to Consumers Who Purchased Deceptively Advertised Arthritis and Joint Pain Relief Supplement Synovia from A.S. Research, LLC ( )
- FTC Approves Administrative Complaint Against Supplement Marketer Health Research Laboratories, LLC ( )
- FTC Sends Letters Warning 20 More Marketers to Stop Making Unsupported Claims That Their Products and Therapies Can Effectively Prevent or Treat COVID-19 ( )
- FTC Refunds More Than $76,000 to Consumers Who Bought Deceptively Marketed “Miracle” Pain Cure for Older Adults ( )
- FTC Refunds More Than $110,000 to Consumers Who Bought StimTein Joint Pain Relief Pills ( )
- FTC Refunds Almost $3.9 Million to Purchasers of Deceptively Advertised Quell Wearable Pain-Relief Device ( )
- FTC Testifies At an Oversight Hearing before the Senate Commerce Committee ( )
- FTC Acts Against Online Sellers That Falsely Promised Fast Delivery of Facemasks and Other Personal Protective Equipment ( )
- FTC Sues California Marketer of $23,000 COVID-19 “Treatment” Plan ( )
- FTC Testifies Before Congress on Efforts to Combat COVID-19-related Scams ( )